A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Trial Profile

A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Carfilzomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 12 Dec 2017 Results (n=72; data cut off May 1, 2017)presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 20 Nov 2017 Planned number of patients changed from 127 to 102.
    • 20 Nov 2017 Planned End Date changed from 1 Sep 2019 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top